SSA
VBIO

Schonfeld Strategic Advisors’s Valion Bio VBIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed -$42K – 2932
2021
Q4 		$42K Buy
+6
New +$44K ﹤0.01% 1958

Other funds holding VBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Schonfeld Strategic Advisors's VBIO Position: Q1 2022 in Review

Schonfeld Strategic Advisors sold out of Valion Bio (VBIO) in Q1 2022, closing a stake of 6 shares — an estimated $42K sold.

Schonfeld Strategic Advisors first reported a position in VBIO in Q4 2021 and held it in 1 quarter. The position peaked at $42K in Q4 2021. 5 funds tracked by Wall St. Rank hold VBIO as of Q1 2022.

  • Schonfeld Strategic Advisors reported no remaining Valion Bio position as of Q1 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 6 Valion Bio shares in Q1 2022, an estimated $42K.
  • Schonfeld Strategic Advisors first reported a position in Valion Bio in Q4 2021 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Valion Bio position peaked at $42K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Valion Bio as of Q1 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2022, filed 16 May 2022.